

644 104  
BEST AVAILABLE COPY

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP


600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER  
PARTNER

INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM  
DIRECT DIAL: 512/536-3184



RECEIVED

SEP 05 2001

TECH CENTER 1600/2900

FILE: UTSD:795US

August 30, 2001

CERTIFICATE OF MAILING  
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

August 30, 2001

Date

Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/845,612 "A CLASS OF 12MER PEPTIDES THAT INHIBIT THE FUNCTION  
OF THE MITOTIC CHECK POINT PROTEIN MAD2" - Hongtao Yu, et al.

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A17, B1-B6, C1-C25).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10101381/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl: as noted